Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Genetic Epidemiology of Responses to Antihypertensives

Trial Profile

Genetic Epidemiology of Responses to Antihypertensives

Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2013

At a glance

  • Drugs Candesartan cilexetil (Primary) ; Hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms GERA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top